A 10-minute prototype assay for tissue degradation monitoring in clinical specimens

Experimental and Molecular Pathology

Volumn 99, Issue 1, 2015, Pages 86-94

  Sun, Jia ^a,b   Kil, Catherine ^b   Stankewich, Michael C ^b   Yao, Zhi ^a   Li, Jie ^b   Vortmeyer, Alexander O ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alpha II spectrin; Calpain; Degradation; Fluorescence Resonance Energy Transfer (FRET); Specimen quality

Indexed keywords

ALPHA II SPECTRIN; CALPAIN; SPECTRIN; UNCLASSIFIED DRUG; RECOMBINANT PROTEIN;

10 MINUTE PROTOTYPE ASSAY; ADULT; ANALYTICAL PARAMETERS; ANIMAL TISSUE; ARTICLE; ASSAY; CONTROLLED STUDY; CORRELATION ANALYSIS; DEGRADATION; EXOME; EXPRESSION VECTOR; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HUMAN CELL; IMMUNOASSAY; IN VITRO STUDY; MICROARRAY ANALYSIS; MOLECULAR CLONING; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN PURIFICATION; QUALITY CONTROL; TISSUE DEGRADATION INDICATOR; TISSUE DEGRADATION MONITORING; TISSUE SECTION; ANIMAL; C57BL MOUSE; CELL CULTURE; DNA SEQUENCE; GENETICS; HEK293 CELL LINE; LABORATORY DIAGNOSIS; METABOLISM; PIG; PROCEDURES; REPRODUCIBILITY;

ANIMALIA; SUS;

ANIMALS; CALPAIN; CELLS, CULTURED; EXOME; FLUORESCENCE RESONANCE ENERGY TRANSFER; HEK293 CELLS; HUMANS; MICE; MICE, INBRED C57BL; MICROARRAY ANALYSIS; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS; SEQUENCE ANALYSIS, DNA; SPECIMEN HANDLING; SPECTRIN; SWINE;

EID: 84930677953     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2015.05.009     Document Type: Article

References (46)

1. Albanell J., et al. Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). Clin. Transl. Oncol. 2009, 11:363-375.
2. Anagnostou V.K., et al. Analytic variability in immunohistochemistry biomarker studies. Cancer Epidemiol. Biomarkers Prev. 2010, 19:982-991.
3. Bai Y., et al. Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables. Lab. Investig. 2011, 91:1253-1261.
4. Bartlett J.M., et al. HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods. J. Clin. Pathol. 2012, 64:649-653.
5. Bennett V., Baines A.J. Spectrin and ankyrin-based pathways: metazoan inventions for integrating cells into tissues. Physiol. Rev. 2001, 81:1353-1392.
6. Brown T.L., et al. Transforming growth factor beta induces caspase 3-independent cleavage of alphaII-spectrin (alpha-fodrin) coincident with apoptosis. J. Biol. Chem. 1999, 274:23256-23262.
7. Cappuzzo F., et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 2004, 96:1133-1141.
8. Chivukula M., et al. Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs resection specimens for equivocal (immunohistochemical score 2+) cases. Mod. Pathol. 2008, 21:363-368.
9. Clark V.E., et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 2013, 339:1077-1080.
10. Cross S.S., et al. Does delay in fixation affect the number of mitotic figures in processed tissue?. J. Clin. Pathol. 1990, 43:597-599.
11. Cummings R.T., et al. A peptide-based fluorescence resonance energy transfer assay for Bacillus anthracis lethal factor protease. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:6603-6606.
12. De Angelis M., et al. NADP-glutamate dehydrogenase activity in nonstarter lactic acid bacteria: effects of temperature, pH and NaCl on enzyme activity and expression. J. Appl. Microbiol. 2010, 109:1763-1774.
13. De Cecco L., et al. Impact of biospecimens handling on biomarker research in breast cancer. BMC Cancer 2009, 9:409.
14. Fox J.E., et al. Spectrin is associated with membrane-bound actin filaments in platelets and is hydrolyzed by the Ca2+-dependent protease during platelet activation. Blood 1987, 69:537-545.
15. Glantz S.B., et al. Sequential degradation of alphaII and betaII spectrin by calpain in glutamate or maitotoxin-stimulated cells. Biochemistry 2007, 46:502-513.
16. Hammond M.E., et al. Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. J. Clin. Oncol. 2012, 29:e458.
17. Harris A.S., et al. The calmodulin-binding site in alpha-fodrin is near the calcium-dependent protease-I cleavage site. J. Biol. Chem. 1988, 263:15754-15761.
18. Hindorff L.A., et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:9362-9367.
19. Hindorff L.A., et al. A catalog of published genome-wide association studies (Accessed (May 21, 2013)). http://www.genome.gov/gwastudies(NIH/NHGRI).
20. Huh G.Y., et al. Calpain proteolysis of alpha II-spectrin in the normal adult human brain. Neurosci. Lett. 2001, 316:41-44.
21. Kisselev A.F., et al. Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J. Biol. Chem. 2006, 281:8582-8590.
22. Kizhatil K., et al. Ankyrin-G and beta2-spectrin collaborate in biogenesis of lateral membrane of human bronchial epithelial cells. J. Biol. Chem. 2007, 282:2029-2037.
23. Kyla-Puhju M., et al. Activity of porcine muscle glycogen debranching enzyme in relation to pH and temperature. Meat Sci. 2005, 69:143-149.
24. Li J., et al. Intrinsic indicators for specimen degradation. Lab. Investig. 2013, 93:242-253.
25. Moatamed N.A., et al. Effect of ischemic time, fixation time, and fixative type on HER2/neu immunohistochemical and fluorescence in situ hybridization results in breast cancer. Am. J. Clin. Pathol. 2012, 136:754-761.
26. Muresan V., et al. Dynactin-dependent, dynein-driven vesicle transport in the absence of membrane proteins: a role for spectrin and acidic phospholipids. Mol. Cell 2001, 7:173-183.
27. Nakajima E., et al. Calpain, not caspase, is the causative protease for hypoxic damage in cultured monkey retinal cells. Invest. Ophthalmol. Vis. Sci. 2011, 52:7059-7067.
28. Nedrelow J.H., et al. c-Src binds alpha II spectrin's Src homology 3 (SH3) domain and blocks calpain susceptibility by phosphorylating Tyr1176. J. Biol. Chem. 2003, 278:7735-7741.
29. Nicolas G., et al. Tyrosine phosphorylation regulates alpha II spectrin cleavage by calpain. Mol. Cell. Biol. 2002, 22:3527-3536.
30. Pinhel I.F., et al. Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer. Breast Cancer Res. 2010, 12:R76.
31. Sauter G., et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J. Clin. Oncol. 2009, 27:1323-1333.
32. Selvarajan S., et al. Detection of HER2/neu gene amplification in archival paraffin-embedded breast cancer tissues by fluorescence in situ hybridization. Histochem. Cell Biol. 2003, 120:251-255.
33. Simonovic M., et al. Structure of the calmodulin alphaII-spectrin complex provides insight into the regulation of cell plasticity. J. Biol. Chem. 2006, 281:34333-34340.
34. Stabach P.R., et al. Site-directed mutagenesis of alpha II spectrin at codon 1175 modulates its mu-calpain susceptibility. Biochemistry 1997, 36:57-65.
35. Stankewich M.C., et al. Targeted deletion of betaIII spectrin impairs synaptogenesis and generates ataxic and seizure phenotypes. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:6022-6027.
36. Striebel J.M., et al. The equivocally amplified HER2 FISH result on breast core biopsy: indications for further sampling do affect patient management. Am. J. Clin. Pathol. 2008, 129:383-390.
37. Suzuki M., et al. Caspase-3 sensitive signaling in vivo in apoptotic HeLa cells by chemically engineered intramolecular fluorescence resonance energy transfer mutants of green fluorescent protein. Biochem. Biophys. Res. Commun. 2005, 330:454-460.
38. Takatsuka K., et al. A novel Ca2+ indicator protein using FRET and calpain-sensitive linker. Biochem. Biophys. Res. Commun. 2005, 336:316-323.
39. Tolles J., et al. Optimal tumor sampling for immunostaining of biomarkers in breast carcinoma. Breast Cancer Res. 2011, 13. R51.
40. Vanderklish P.W., et al. Marking synaptic activity in dendritic spines with a calpain substrate exhibiting fluorescence resonance energy transfer. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:2253-2258.
41. Wang K.K., et al. Simultaneous degradation of alphaII- and betaII-spectrin by caspase 3 (CPP32) in apoptotic cells. J. Biol. Chem. 1998, 273:22490-22497.
42. Werner M., et al. Effect of formalin tissue fixation and processing on immunohistochemistry. Am. J. Surg. Pathol. 2000, 24:1016-1019.
43. Yamashita H., et al. Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer. Breast Cancer Res. 2005, 7:R753-R764.
44. Zadran S., et al. Brain-derived neurotrophic factor and epidermal growth factor activate neuronal m-calpain via mitogen-activated protein kinase-dependent phosphorylation. J. Neurosci. 2010, 30:1086-1095.
45. Zhang W., et al. The major calpain isozymes are long-lived proteins. Design of an antisense strategy for calpain depletion in cultured cells. J. Biol. Chem. 1996, 271:18825-18830.
46. Zhang Z., et al. Multiple alphaII-spectrin breakdown products distinguish calpain and caspase dominated necrotic and apoptotic cell death pathways. Apoptosis 2009, 14:1289-1298.